semaglutide
Explore Tirzepatide vs Semaglutide Mortality Edge 2026
Explore Tirzepatide vs Semaglutide Mortality Edge 2026 Tirzepatide appears to be the safer GLP-1/GIP dual agonist for patients with heart failure, showing lower mortality and fewer serious cardiac events than semaglutide. Recent real-world and trial data back this claim, while guideline bodies are beginning to adjust their recommendations. Medical